By: Sabrina Serani From: targetedonc.com Key Takeaways Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall response rate compared to chemotherapy. Trastuzumab deruxtecan plus pertuzumab demonstrated significant efficacy in HER2+ breast cancer, marking the first major first-line improvement in over a decade. Emiltatug ledadotin was fast-tracked by the FDA for advanced breast cancer, showing promise …
Breast-Conserving Surgery Safe for Deeply Seated Breast Cancer
By: Deborah L. Ungerleider, MD From: medscape.com The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways When performing breast-conserving surgery, the retroglandular approach via incision in the inframammary fold for excision of a retroglandular tumor is feasible and safe. This incision gives better cosmetic results while allowing …
HER2+ Breast Cancer: Key Takeaways From HER2CLIMB
By: Giuseppe Curigliano, MD, PhD From: onclive.com An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer. Giuseppe Curigliano, MD, PhD: Tucatinib is a highly selective HER2 [human epidermal growth factor receptor 2]–directed tyrosine kinase inhibitor. The specificity …
Black Women Face Barriers to Breast Cancer Treatment, Study Finds
By: Kara-Marie Hall, RN, BSN, CCRN From: verywellhealth.com Key Takeaways Recent research shows Black women are less likely to be offered hypofractionated radiation therapy as an option for breast cancer treatment. Black women face several inequalities that start from the moment they seek a diagnosis. Access to breast cancer treatment can depend on trust, awareness, and financial resources. Improving healthcare …